tirzepatide surpass 5 SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Read now: The SURPASS-EARLY trial

30 kg/m or greater (obese), or 27 kg/m or greater (overweight) in the presence of at least one weight-related comorbid condition Saxenda also has indications for pediatric patients

Pancreatitis is a recognised class warning for GLP-1 receptor agonists, as noted in the prescribing information (SmPCs) for semaglutide and tirzepatide and in MHRA Drug Safety communications

Weeks 12: Reduced appetite and fewer cravings Weeks 48: Weight loss becomes noticeable Months 36: 510% body weight reduction is common Months 612+: Sustainable long-term results with lifestyle support Patient Success Story One patient lost 25.8 pounds over 9 months while preserving muscle mass and improving overall metabolic health

Add lemon or cucumber for flavor or use other water enhancers to ensure you are getting enough water

Tong et al., 2016)